title: L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
abstract: Brain edema sufficient to cause intracranial hypertension and brain herniation remains a major cause of mortality in acute liver failure (ALF). Studies in experimental animal models of ALF suggest a role for ammonia in the pathogenesis of both encephalopathy and brain edema in this condition. As part of a series of studies to evaluate the therapeutic efficacy of ammonia-lowering agents, groups of rats with ALF caused by hepatic devascularization were treated with L-ornithine-L-aspartate (OA), an agent shown previously to be effective in reducing blood ammonia concentrations in both experimental and human chronic liver failure. Treatment of rats in ALF with infusions of OA (0.33 g/kg/h, intravenously) resulted in normalization of plasma ammonia concentrations and in a significant delay in onset of severe encephalopathy. More importantly, brain water content was significantly reduced in OA-treated rats with ALF. These protective effects of OA were accompanied by increased plasma concentrations of several amino acids including glutamate, gamma-aminobutyric acid (GABA), taurine, and alanine, as well as the branched-chain amino acids, leucine, isoleucine, and valine. Increased availability of glutamate following OA treatment provides the substrate for the major ammonia-removal mechanism (glutamine synthetase). Plasma (but not cerebrospinal fluid) glutamine concentrations were increased 2-fold (P <.02) in OA-treated rats, consistent with increased muscle glutamine synthesis. Direct measurement of glutamine synthetase activities revealed a 2-fold increase following OA treatment. These findings demonstrate a significant ammonia-lowering effect of OA together with a protective effect on the development of encephalopathy and brain edema in this model of ALF.
authors.affiliation: Neuroscience Research Unit, Centre Hospitalier de l'Université de Montréal (Campus Saint-Luc), Montreal, Que., Canada H2X 3J4.
authors.forename: C
authors.initials: C
authors.lastname: Rose
authors.forename: A
authors.initials: A
authors.lastname: Michalak
authors.forename: K V
authors.initials: KV
authors.lastname: Rao
authors.forename: G
authors.initials: G
authors.lastname: Quack
authors.forename: G
authors.initials: G
authors.lastname: Kircheis
authors.forename: R F
authors.initials: RF
authors.lastname: Butterworth
mesh_terms: D000641:Ammonia / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D000818:Animals; D001929:Brain Edema / Q000517:prevention & control*; D004151:Dipeptides / Q000627:therapeutic use*; D018698:Glutamic Acid / Q000378:metabolism; D017114:Liver Failure, Acute / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D004151:Dipeptides; D018698:Glutamic Acid; D000641:Ammonia; C002939:ornithylaspartate